Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

To be considered for this study, you would generally need to have secondary Hemophagocytic Lymphohistiocytosis (sHLH). For the part of the study currently recruiting, we are looking for adults who have been recently diagnosed with sHLH, especially if it's connected to cancer. We are also interested in adults with newly diagnosed sHLH not caused by cancer, and teenagers aged 13 to 17 with newly diagnosed sHLH.

There's also a specific group for children aged 6 to 12. Initially, this group is for those whose sHLH has not responded well to other treatments. Once that first group is complete, we'll be looking for 6 to 12-year-olds who have been newly diagnosed with sHLH.

There are also some reasons why you might not be able to join. For example, if you have a different type of HLH (called primary or hereditary HLH), or if your sHLH has not fully responded to previous treatments (unless you are in the specific 6-12 year old group mentioned). Also, if you have very severe problems with your organs or other significant health conditions that might make taking part unsafe, you might not be able to participate.

If you join this study, you would receive the new medication, ELA026. This medicine will be given either through a drip into your vein (intravenously) or as an injection under your skin (subcutaneously). The study involves regular visits to the clinic for check-ups, blood tests, and other assessments to monitor your health and how the medicine is working. These visits help the study team understand the safety and effectiveness of ELA026. The total duration of your participation will depend on the specific part of the study you are in, and whether the treatment is helpful for you. You would have ongoing follow-up to track your progress.